Saturday 17 October 2026 Export BFRI’s income statement to Excel — free account

Biofrontera Inc.

BFRI Healthcare Drug Manufacturers Specialty & Generic

Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.9%, EPS grew 91.2%, free cash flow grew 45.6% and total debt rose 6.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

0.82 0.03 −3.53%

Follow BFRI

Alert me

Market cap: $12.6M
P/E: 0.0×
Fwd P/E: −4.1×
Dividend yield: —
F-score: 3/9
Altman Z: −5.67
Beneish M: 0.02
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.65%

Capital & Financial Ratios $m

Market Cap 12.58

Revenue 46.17

Net Income (6.36)

Free Cash Flow (7.93)

Net Debt (0.05)

Current Ratio 1.18

Debt/Equity 0.78

P/E ratio 0.00

Fwd P/E (4.07)

P/S ratio 0.23

P/B ratio 1.78

Past 5Y EPS Growth —

This Y EPS Growth 62.50%

Next Y EPS Growth 151.28%

Next Y revenue growth 10.66%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 44.46%

10-year low 10-year high

P/B against its own 10 years 59.19%

10-year low 10-year high

EV/Sales against its own 10 years 64.58%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	6	6	5
Receivables	5	5	7	6
Inventory	11	7	1	1
Other	5	2	1	0
	23	21	18	12

	2023	2024	2025	Q'26
Payables	9	7	7	5
ST’ Debt	4	—	—	—
Other	—	—	—	—
	18	12	12	11

Compound Annual Growth %

	10y	5y	3y
Sales	—	17.21%	13.30%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	12.45%	(24.00%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	10	12	—	—	—
’25	9	9	7	17	42
’24	8	8	9	13	37
’23	9	6	9	11	34
’22	10	4	4	10	29
’21	5	6	4	9	24
’20	5	2	3	—	19

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	(2)	—	—	—
’25	(4)	(3)	(4)	(2)	(13)
’24	(3)	(5)	(1)	(1)	(10)
’23	(4)	(10)	(2)	(9)	(25)
’22	(2)	0	(6)	(8)	(16)
’21	(3)	(1)	(1)	(21)	(27)
’20	(7)	(4)	(12)	(1)	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	(2)	—	—	—
’25	(4)	(3)	(4)	(2)	(13)
’24	(3)	(5)	(1)	(1)	(10)
’23	(4)	(10)	(2)	(9)	(25)
’22	(2)	0	(6)	(8)	(16)
’21	(3)	(1)	(1)	(21)	(27)
’20	(7)	(4)	(12)	(1)	(12)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.41)	(0.05)	—	—	—
’25	(0.47)	(0.57)	(0.62)	0.63	(1.04)
’24	(2.88)	(0.05)	(0.98)	0.69	(3.22)
’23	(5.60)	(7.23)	(4.64)	1.65	(13.02)
’22	6.40	(1.00)	(2.20)	(2.80)	(0.60)
’21	(8.83)	(9.15)	(40.00)	(25.80)	(85.60)
’20	(0.34)	(0.31)	(59.70k)	—	(9.59k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	45.00	15.00	2.66	0.61	0.54	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	292.60	147.60	22.40	3.90	1.87
People
People	Employees	—	—	—	—	56	69	81	85	93	94
	Revenue/emp, $m	—	—	—	0.00	0.34	0.35	0.35	0.40	0.40	0.44
Income, $m
Income, $m	Revenue	—	—	—	26	19	24	29	34	37	42
	Gross margin, %	—	—	—	50.06	51.90	47.13	47.04	48.80	50.14	73.71
	EBT	—	—	—	(11)	(11)	(38)	(1)	(20)	(18)	(11)
	EBT margin, %	—	—	—	(41.82)	(57.95)	(156.25)	(2.12)	(59.04)	(47.53)	(25.20)
	Net income	—	0	—	(11)	(11)	(38)	(1)	(20)	(18)	(11)
	Depreciation	—	—	—	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	—	43.13	17,135.45	54.72	27.13	22.03	6.77	4.10
	Earnings	—	—	—	(18.09)	(9,589.35)	(85.60)	(0.60)	(13.02)	(3.22)	(1.04)
	Cash flow	—	—	—	(62.07)	(11,244.55)	(60.66)	(15.33)	(16.10)	(1.86)	(1.31)
	Capex	—	—	—	0.00	0.00	(0.02)	(0.04)	0.00	(0.01)	0.00
	Free cash flow	—	—	—	(62.07)	(11,244.55)	(60.69)	(15.36)	(16.10)	(1.87)	(1.31)
	Book value	—	—	—	(49.72)	5,298.18	25.74	22.59	3.10	0.80	1.03
	Shares, m	—	—	—	1	0	0	1	2	6	10
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	28.17	0.00	0.00	0.00
	P/S	—	—	—	1.94	1.94	2.75	0.62	0.13	0.16	0.14
	P/B	—	—	—	0.00	0.00	5.84	0.75	0.90	1.36	0.55
	EV/Sales	—	—	—	1.85	1.85	1.73	(0.30)	0.22	0.12	0.10
	EV/FCF	—	—	—	(5.25)	(5.25)	(1.56)	0.53	(0.30)	(0.44)	(0.32)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(38)	(12)	(27)	(16)	(25)	(10)	(13)
	Capex	—	—	—	(1)	—	0	0	0	0	0
	Free cash flow	—	—	—	(38)	(12)	(27)	(16)	(25)	(10)	(13)
Balance, $m
Balance, $m	Working capital	—	—	—	12	15	33	22	5	9	6
	Total debt	—	—	—	38	—	—	1	4	4	5
	Net debt	—	—	—	31	(8)	(25)	(26)	2	(2)	(2)
	Shareholders’ equity	—	—	—	(30)	6	11	24	5	4	10
Returns, %
Returns, %	ROA	—	—	—	(76.39)	(41.55)	(97.50)	(1.23)	(51.08)	(70.99)	(41.59)
	ROIC	—	—	—	0.00	0.00	0.00	0.00	(194.79)	(410.70)	(81.82)
	ROE	—	—	—	90.20	90.24	(439.39)	(3.63)	(140.43)	(384.98)	(141.30)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc.	$26.5M	0.2×	—	—	n/m	+82.01% (above 0%: growing)	0.00%	0.00%	Compare
TXMD TherapeuticsMD, Inc.	$22.3M	— (loss-making)	18.9×	−8.72% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+104.46% (above 0%: growing)	100.00%	(93.90%)	Compare
AYTU Aytu BioPharma, Inc.	$21.8M	— (loss-making)	— (loss-making)	+6.42% (above 0%: growing)	n/m	+57.72% (above 0%: growing)	64.63%	(4.82%)	Compare
UPC Universe Pharmaceuticals INC	$20.9M	— (loss-making)	4.1×	−23.98% (below 0%: shrinking)	−110.15% (below 0%: shrinking)	−84.99% (below 0%: shrinking)	32.57%	0.00%	Compare
BGXXQ Bright Green Corporation	$13.9M	— (loss-making)	—	—	n/m	−1.46% (below 0%: shrinking)	0.00%	0.00%	Compare
BFRI Biofrontera Inc.	$12.6M	— (loss-making)	— (loss-making)	+32.92% (above 0%: growing)	n/m	+45.57% (above 0%: growing)	79.92%	(4.37%)
INM InMed Pharmaceuticals Inc.	$7.3M	— (loss-making)	—	−26.22% (below 0%: shrinking)	n/m	−40.43% (below 0%: shrinking)	22.46%	0.00%	Compare
APUS Apimeds Pharmaceuticals US, Inc.	$6.6M	— (loss-making)	—	—	n/m	−67.94% (below 0%: shrinking)	—	0.00%	Compare
SNOA Sonoma Pharmaceuticals, Inc.	$5.5M	— (loss-making)	— (loss-making)	+59.55% (above 0%: growing)	n/m	+69.31% (above 0%: growing)	40.23%	(0.62%)	Compare
Median of peers	$17.4M	—	—	−8.72%	—	+28.13%	32.57%	0.00%

All 86 Drug Manufacturers Specialty & Generic stocks →

Biofrontera Inc. (BFRI) key facts

Strength: Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024.
Biofrontera Inc. (BFRI) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BFRI traded at $0.82, a market capitalization of $12.6 million.
Return on equity was −141.3% and debt-to-equity 0.78.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −5.67 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.